Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 15, 2026European Journal Of Haematology

Bridging Trials and Real Life in Fixed‐Duration BTKi –Venetoclax for CLL : A Delphi‐Enhanced Synthesis Incorporating Artificial Intelligence ( AI ) Benchmarks

View Full Paper
Ask AI
Bookmark
Share

Authors

SMStefano MolicaMLMariano LucignanoMVMaria Rosaria Villa

Discussion

Loading...

Member takes

Overview

Delphi process assesses optimal venetoclax therapy for CLL, suggesting a pragmatic approach for patient selection.

Key Points

  • The study aims to enhance patient selection for effective BTKi partners in venetoclax regimens for CLL by bridging clinical trials and real-world practice.
  • Engaged nine hematologists in a Delphi process to evaluate decision-making in CLL therapy.
  • Assessed three domains: comorbidities, genomics, and logistics in BTKi–venetoclax regimens.
  • Conducted a systematic literature review and defined consensus at ≥ 75% agreement through two Delphi rounds.
  • Utilized AI benchmarking with ChatGPT-4 for decision support assessments.
  • Consensus was achieved on 83.3% of evaluated statements.
  • Recommendations favored FD BTKi–venetoclax for fit, younger patients with low- or intermediate-genomic risk.
  • Continuous BTKi therapy preferred for patients with low-intermediate cardiovascular risk over FD ibrutinib–venetoclax.
  • Adverse genomic features and logistical issues led to preferences for continuous second-generation BTKi therapy.
  • AI benchmarking showed fair concordance with clinical evidence, indicating potential for human–AI decision support.

Cite This Study

Molica et al. (2026) studied this question.

synapsesocial.com/papers/69df2c77e4eeef8a2a6b1a0dhttps://doi.org/10.1111/ejh.70195
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Consensus on optimal use of fixed-duration BTK inhibitor and venetoclax therapy in CLL: A delphi study comparing human expertise and AI methodologies2025
  2. 2Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025
  3. 3Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis2025
  4. 4Real-world overall survival outcomes of BTK inhibitors vs. venetoclax-based therapy as second-line treatment for chronic lymphocytic leukemia.2026
  5. 5Real-world outcomes of bruton tyrosine kinase inhibitors versus venetoclax in chronic lymphocytic leukemia.2026